+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 2Hours +
All Genders
ID06974994

Studying How Synbiotic Supplements Can Protect Newborns Exposed to Antibiotics at Birth from Obesity and Infections

Led by Turku University Hospital · Updated on 2025-05-16

125

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether giving a synbiotic supplement to newborns exposed to antibiotics at birth can change their gut microbiota and reduce risks of obesity, chronic diseases, and respiratory infections. This randomized, double-blind, placebo-controlled study will enroll 125 mother-child pairs to explore how early microbial changes impact long-term health. Infants will be randomly assigned to receive either a synbiotic supplement containing Bifidobacterium bifidum and human milk oligosaccharides or a placebo made of maltodextrin for two months. After the intervention, their growth and health will be closely monitored at a research clinic for two years to assess the supplements effects. Participants will have regular check-ups to measure body mass index, height, weight, growth speed, and microbiome composition from birth up to 24 months. The study will also analyze the mothers and breast milk microbiomes as well as hormonal and inflammatory markers in the first six months. Researchers will track respiratory infections and overall health outcomes throughout the two-year follow-up period.

CONDITIONS

Brief Title

Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation

Research Team

P

Paula Tähtinen, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here